In consideration of the extensive role of XPD in digestive tract cancers, we performed a meta-analysis of all 37 eligible case–control studies: oral cancer, esophageal cancer, gastric cancer http://www.sciencedirect.com/science/article/pii/S0188440911000853 - bib10and colorectal cancer, to derive a more precise association of XPD Lys751Gln polymorphism and different types of digestive tract cancers risk. Here, ERCC2 is linked to gastric cancer.